Trial Profile
PCSK9 Inhibition After Heart Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- 22 May 2022 Planned End Date changed from 1 Sep 2023 to 28 Feb 2025.
- 22 May 2022 Planned primary completion date changed from 1 Sep 2023 to 28 Feb 2025.
- 04 Aug 2019 Status changed from not yet recruiting to recruiting.